Almac Diagnostic Services Ltd (Almac Diagnostic Services), a subsidiary of Almac Group Ltd, is a medical diagnostic company. It discovers, develops and commercializes diagnostic tests including companion diagnostics. The company provides products pipeline such as ColDx, DDRD, AADx, prostate Dx and MEK Dx among others. Almac Diagnostic Services provides pre-clinical biomarker discovery to companion diagnostic development including regulatory submissions and commercialization. The company provides applications such as patient selection, and are utilized in phase I to phase III registrational clinical trials. It operates laboratories in the US and the UK. Almac Diagnostic Services is headquartered in Craigavon, the UK.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
The report analyzes all pipeline products in development for the company Almac Diagnostic Services Ltd
The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
The report provides detailed description of products in development, technical specification and functions
The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
To formulate effective Research & Development strategies
Develop market-entry and market expansion strategies
Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note:Some sections may be missing if data is unavailable for the company
Dec 08, 2021: Almac Diagnostic Services claraT report assists researchers in uncovering new oncology findings
Sep 26, 2019: Almac’s unique gene expression report enables cancer researchers to discover exciting new insights
Jun 05, 2019: Almac Group announces CE mark of diagnostic assay to support Turning Point Therapeutics’ pivotal TRIDENT-1 clinical trial
May 06, 2019: Turning Point Therapeutics and Almac Diagnostic Services announce approval of an Investigational Device Exemption for the Companion Diagnostic Assay to the Registrational TRIDENT-1 Clinical Study
Apr 23, 2019: Almac forms alliance with academia for new oesophageal cancer test
Apr 18, 2019: Almac Group partner with Queen’s researchers to pioneer potentially life-changing Oesophageal Cancer test
Mar 27, 2019: Almac Group launches upgraded version of claraT – a unique, software-driven gene expression report
Oct 19, 2018: Almac Group launches claraT – A unique, software-driven gene expression report
Feb 12, 2018: DNAnexus Launches NGS Clinical Trial Solution
Oct 23, 2017: Queens University Belfast Leads Largest Study of its Kind to Transform Prostate Cancer Treatment